Darolutamide Delays Metastasis in High-risk CRPC Patients, Phase 3 Trial Shows

Darolutamide Delays Metastasis in High-risk CRPC Patients, Phase 3 Trial Shows
Adding the androgen receptor inhibitor darolutamide to androgen deprivation therapy (ADT) extends by 22 months the time men with castration-resistant prostate cancer live without metastasis, without increasing the incidence of adverse events, results from a Phase 3 trial show. The treatment also extended survival, time to pain progression, time until chemotherapy was needed, and kept patients alive and progression-free for longer periods than ADT alone, researchers reported. Findings from the ARAMIS Phase 3 trial (NCT02200614) were recently presented during the 2019 Genitourinary Cancers Symposium in San Francisco. They were also published in The New England Journal of Medicine in the study "Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer." Metastasis is a major cause of complications and death among men with prostate cancer, and investigators have been focusing on the prevention of metastasis in men at risk, which may significantly extend their lives and improve their quality of life. Currently, two androgen receptor inhibitors — 
Subscribe or to access all post and page content.